

Oncology

Review

- 259 "Logic-Based Medicine" Is More Feasible than "Evidence-Based Medicine" in the Local Treatment for Hepatocellular Carcinoma**
 Sakon, M. (Osaka); Kobayashi, S. (Saitama); Wada, H. (Osaka); Eguchi, H. (Saitama); Marubashi, S. (Fukushima); Takahashi, H. (Osaka); Akita, H.; Gotoh, K. (Saitama); Yamada, D.; Asukai, K.; Hasegawa, S.; Ohue, M.; Yano, M. (Osaka); Nagano, H. (Yamaguchi)

Clinical Studies

- 267 Hepatic Arterial Infusion Chemotherapy of 5-Fluorouracil for Patients with Unresectable Liver Metastases from Colorectal Cancer Refractory to Standard Systemic Chemotherapy: A Multicenter Retrospective Study**
 Sato, Y.; Inaba, Y. (Nagoya); Aramaki, T. (Shizuoka); Sone, M. (Tokyo); Morita, Y. (Kobe); Nishiofuku, H.; Tanaka, T. (Kashihara); Miyazaki, M. (Maebashi); Matsueda, K.; Arai, Y. (Tokyo)
- 273 Indication and Prognostic Significance of Conversion Surgery in Patients with Liver Metastasis from Gastric Cancer**
 Arigami, T.; Matsushita, D.; Okubo, K.; Kawasaki, Y.; Iino, S.; Sasaki, K.; Noda, M.; Kita, Y.; Mori, S.; Kurahara, H.; Maemura, K.; Yanagita, S.; Uenosono, Y.; Ishigami, S.; Natsugoe, S. (Kagoshima)
- 280 Prognostic Impact of Postoperative Complications following Salvage Esophagectomy for Esophageal Cancer after Definitive Chemoradiotherapy**
 Sugimura, K.; Miyata, H.; Shinno, N.; Ushigome, H.; Asukai, K.; Hara, H.; Hasegawa, S.; Yamada, D.; Yamamoto, K.; Haraguchi, N.; Nishimura, J.; Motoori, M.; Wada, H.; Takahashi, H.; Yasui, M.; Omori, T.; Ohue, M.; Yano, M. (Osaka)
- 289 Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFI) for Refractory Advanced Gastroesophageal Cancer**
 Rogers, J.E.; Xiao, L.; Trail, A.; Blum Murphy, M.; Palmer, M.; Ajani, J.A. (Houston, TX)

295 Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma

Hiraoka, A. (Matsuyama); Kumada, T. (Gifu); Tada, T. (Himeji); Fukunishi, S. (Osaka); Atsukawa, M. (Tokyo); Hirooka, M. (Toon); Tsuji, K. (Sapporo); Ishikawa, T. (Niigata); Takaguchi, K. (Takamatsu); Kariyama, K. (Okayama); Itobayashi, E. (Asahi); Tajiri, K. (Toyama); Shimada, N. (Kashiwa); Shibata, H. (Tokushima); Ochi, H. (Matsuyama); Kawata, K. (Hamamatsu); Toyoda, H. (Gifu); Ohama, H. (Osaka); Tsutsui, A. (Takamatsu); Itokawa, N.; Hayama, K.; Arai, T. (Tokyo); Imai, M. (Niigata); Nakamura, S. (Himeji); Michitaka, K. (Matsuyama); Hiasa, Y. (Toon); Kudo, M. (Osaka); Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group

Clinical Translational Research

- 303 High Serum OX40 and OX40 Ligand (OX40L) Levels Correlate with Reduced Survival in Patients with Advanced Lung Adenocarcinoma**
 Kashima, J.; Okuma, Y.; Hosomi, Y.; Hishima, T. (Tokyo)
- 311 Human Telomerase Reverse Transcriptase Gene Promoter Mutation in Serum of Patients with Hepatocellular Carcinoma**
 Ako, S.; Nouso, K.; Kinugasa, H.; Matsushita, H.; Terasawa, H.; Adachi, T.; Wada, N.; Takeuchi, Y.; Mandai, M.; Onishi, H.; Ikeda, F.; Shiraha, H.; Takaki, A.; Fujioka, S.; Mimura, T.; Okada, H. (Okayama)

Short Communication

- 318 Bullous Pemphigoid and Malignancy in Two Different Hospital Populations: A Retrospective Cohort Review**
 Wright, B.; Halper, K.; Worswick, S. (Los Angeles, CA)